Nausea Medicine Companies

Latest Nausea Medicine Companies Update

• 
  Apr 2023: AstraZeneca's market value has surpassed that of Pfizer, the US rival, almost ten years after the British pharmaceutical company thwarted the latter's hostile takeover attempt. This is a critical turning point in the company's turnaround and for UK plc. All eyes will be on the comments made by pharmaceutical executives regarding the UK as a location for operations and investment in the coming week, when AstraZeneca and GSK, the country's second-largest pharmaceutical company, release their most recent quarterly results and the main trade association, the Association of the British Pharmaceutical Industry, holds its annual conference. The industry and the government are at odds over the enormous rebates the business pays to the National Health Service, which are intended to keep the NHS's drug costs to a minimum. In recent years, Soriot has entirely redesigned AstraZeneca's therapeutic portfolio, which now includes treatments for diabetes, leukemia, lung cancer, including Tagrisso, Calquence, and Farxiga.

• 
  Apr 2023: Pharmaceutical company Cipla and Novartis Pharma AG (Switzerland) have inked a perpetual license deal that will allow Cipla to produce and sell the diabetic medication Galvus and its combination brands starting on January 1, 2026. Galvus, a well-known brand in the Dipeptidyl Peptidase-4 (DPP4) market, particularly for oral diabetic medications, has the potential to make a substantial contribution to Cipla's portfolio. Galvus has recorded sales of ₹268 crore, according to IQVIA (MAT February 2023) statistics.

• Novartis AG (Switzerland)


• Merck & Co., Inc. (US)


• F. Hoffmann-La Roche Ltd (Switzerland)


• GlaxoSmithKline PLC (UK)


• Pfizer Inc. (US)


• Sanofi S.A. (France)


• Mylan NV (US)


• AstraZeneca (UK)


• Cipla Inc. (India)